BeiGene, Ltd. (SHA:688235)
China
· Delayed Price · Currency is CNY 232.98
+11.48 (5.18%)
May 13, 2025, 3:00 PM CST
BeiGene Revenue
BeiGene had revenue of $1.12B USD in the quarter ending March 31, 2025, with 48.64% growth. This brings the company's revenue in the last twelve months to $4.18B, up 51.16% year-over-year. In the year 2024, BeiGene had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
$4.18B
Revenue Growth
+51.16%
P/S Ratio
5.98
Revenue / Employee
$379.62K
Employees
11,000
Market Cap
181.32B CNY
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 39.59B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Aier Eye Hospital Group | 21.81B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |
BeiGene News
- 5 days ago - BeiGene targets $4.9B-$5.3B revenue for 2025 with strong BRUKINSA and pipeline growth - Seeking Alpha
- 5 days ago - BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat - Benzinga
- 6 days ago - BeiGene reports mixed Q1 results; reaffirms FY25 outlook - Seeking Alpha
- 6 days ago - Earnings Scheduled For May 7, 2025 - Benzinga
- 6 days ago - BeiGene Q1 2025 Earnings Preview - Seeking Alpha
- 13 days ago - U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene - Business Wire
- 18 days ago - Summit extends gains as cancer drug outperforms BeiGene’s Tevimbra - Seeking Alpha